NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/03/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization395.93 mln
Float79.28 mln
Earnings Date08/05/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
2.83
Highly suspicious
1-Year Forecast
6.00
Transformational upside
Relative Strength
13
/ 100
Significantly lagging
Debt / Equity
3.92
Highly leveraged
ROE
-430
Deeply negative
Business Description
Editas Medicine is a Cambridge, Massachusetts-based company founded in 2013 that uses CRISPR technology to develop one-time genetic treatments for serious conditions such as high cholesterol, sickle cell disease, and beta thalassemia. Its most advanced treatment, EDIT-401, works by modifying genes to help the body better remove harmful cholesterol from the blood. The company is also working with Juno Therapeutics to create experimental cell-based treatments for cancer and autoimmune conditions.
